<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688138</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2020-169</org_study_id>
    <nct_id>NCT04688138</nct_id>
  </id_info>
  <brief_title>Gut Microbiota and Serum Markers for Cognitive Impairment and Poor Prognosis After Ischemic Stroke</brief_title>
  <official_title>Predictive Value of Gut Microbiota and Serum Markers for Cognitive Impairment and Poor Prognosis After Ischemic Stroke: A Multiple Center Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong 999 Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jinan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-stroke cognitive impairment(PSCI) is one of the most important factors causing&#xD;
      disabilities after stroke. Recent study found that gut microbiota plays a key role in&#xD;
      neurological diseases. Two recent small sample studies reported gut dysbiosis in PSCI&#xD;
      patients. In order to further verify the relationship between PSCI and gut microbiota and the&#xD;
      predictive value of gut microbiota and serum markers for cognitive impairment and poor&#xD;
      prognosis after ischemic stroke. The study intended to collect stool specimens of patients&#xD;
      with acute ischemic stroke and assess their cognitive psychological state, and to establish a&#xD;
      prospective multi-center follow-up cohort to explore the correlation between the dynamic&#xD;
      changes of intestinal flora in patients with stroke and PSCI and poor prognosis of stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mini-Mental State Examination</measure>
    <time_frame>7 days after admission</time_frame>
    <description>A cognitive function screening test ranged 0-30, higher scores mean better cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini-Mental State Examination</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>A cognitive function screening test ranged 0-30, higher scores mean better cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini-Mental State Examination</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>A cognitive function screening test ranged 0-30, higher scores mean better cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment</measure>
    <time_frame>7 days after admission</time_frame>
    <description>A cognitive function screening test ranged 0-30, higher scores mean better cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>A cognitive function screening test ranged 0-30, higher scores mean better cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>A cognitive function screening test ranged 0-30, higher scores mean better cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>2 days after admission</time_frame>
    <description>Results of fecal bacteria by 16s RNA sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Results of fecal bacteria by 16s RNA sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale(mRS)</measure>
    <time_frame>7 days after admission</time_frame>
    <description>A neurological function score scale ranged 0-6, higher scores mean worse neurological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale(mRS)</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>A neurological function score scale ranged 0-6, higher scores mean worse neurological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale(mRS)</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>A neurological function score scale ranged 0-6, higher scores mean worse neurological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale(mRS)</measure>
    <time_frame>12 months after discharge</time_frame>
    <description>A neurological function score scale ranged 0-6, higher scores mean worse neurological outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale(NIHSS)</measure>
    <time_frame>Day 1 of admission</time_frame>
    <description>Neurological function score scale, ranged 0-42, higher scores mean more severe neurological deficit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale(NIHSS)</measure>
    <time_frame>Day 7 of admission</time_frame>
    <description>Neurological function score scale, ranged 0-42, higher scores mean more severe neurological deficit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale(NIHSS)</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Neurological function score scale, ranged 0-42, higher scores mean more severe neurological deficit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale(NIHSS)</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>Neurological function score scale, ranged 0-42, higher scores mean more severe neurological deficit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short chain fatty acids</measure>
    <time_frame>2 days after admission</time_frame>
    <description>A metabolites of gut microbiota from stool, detected by gas chromatography-mass spectrometry (GC-MS) combined technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short chain fatty acids</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>A metabolites of gut microbiota from stool, detected by gas chromatography-mass spectrometry (GC-MS) combined technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trimethylamine-N-Oxide</measure>
    <time_frame>2 days after admission</time_frame>
    <description>A metabolites of gut microbiota in plasm, quantified by stable isotope dilution liquid chromatography tandem mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trimethylamine-N-Oxide</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>A metabolites of gut microbiota in plasm, quantified by stable isotope dilution liquid chromatography tandem mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Untargeted Metabolomics</measure>
    <time_frame>2 days after admission</time_frame>
    <description>Untargeted metabolomics refers to using gas chromatography-mass spectrometry (GC-MS) combined technique, without bias detection of all small molecule metabolites in plasma (mainly the relative molecular weight of 1000 Da endogenous small molecule compounds) levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Untargeted Metabolomics</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>Untargeted metabolomics refers to using gas chromatography-mass spectrometry (GC-MS) combined technique, without bias detection of all small molecule metabolites in plasma (mainly the relative molecular weight of 1000 Da endogenous small molecule compounds) levels.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>ischemic stroke</arm_group_label>
    <description>Patients with ischemic stroke within 7 days of onset</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood plasm; Faeces ;Oral swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ischemic stroke within 7 days of onset&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet the diagnostic criteria for acute ischemic stroke;&#xD;
&#xD;
          -  Aged between 18-75;&#xD;
&#xD;
          -  Onset within 7 days;&#xD;
&#xD;
          -  Sign informed consent and agree to provide relevant medical history data and&#xD;
             biological specimens.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with TIA&#xD;
&#xD;
          -  Severe disturbance of consciousness (NIHSS consciousness score &gt; 1)&#xD;
&#xD;
          -  Previous severe mental disorders and dementia (AD8 score â‰¥ 2)&#xD;
&#xD;
          -  History of cerebral hemorrhage or any stroke within 12 months;&#xD;
&#xD;
          -  Serious systemic diseases including malignant tumors&#xD;
&#xD;
          -  Patients with aphasia and unable to cooperate to complete the Montreal Cognitive&#xD;
             Assessment (MoCA)&#xD;
&#xD;
          -  ALT or AST greater than 2 times the upper limit of normal value or severe liver&#xD;
             disease;&#xD;
&#xD;
          -  GFR less than 30mL/min/1.72m2 or severe kidney disease&#xD;
&#xD;
          -  Alcohol abused, drug use and chemical poisoning history (such as pesticide poisoning)&#xD;
&#xD;
          -  Patients with previous history of gastrointestinal tract or confirmed during&#xD;
             hospitalization&#xD;
&#xD;
          -  Patients who could not collect stool samples within 4 days after admission.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Yin Jia, Master</last_name>
    <phone>+86 13802964883</phone>
    <email>jiajiayin@139.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Mingsi, Master</last_name>
    <phone>+86 13827003570</phone>
    <email>meens19@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, NanFang Hospital, Southern Medical University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Jia, master's degree</last_name>
      <phone>+8613802964883</phone>
      <email>jiajiayin@139.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhang Mingsi</last_name>
      <phone>+8613827003570</phone>
      <email>meens@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Stroke; cognitive impairment; gut microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

